Urologic Cancers

UROLOGIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Multidisciplinary Genetic Tumor Boards: Critical for Interpreting Tumor-Only Sequencing Results

One approach for improving recommendations based on tumor-only sequencing is use of a multidisciplinary genomic tumor board, in which researchers from a variety of backgrounds weigh in on the best way to interpret test results.
The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma

Updated guidelines advised against performing cytoreductive nephrectomy in poor-risk patients.
IL-2 and Metastatic Renal Cell Carcinoma

Despite a challenging toxicity profile, high dose interleukin-2 (HD IL-2), one of the earliest-approved immunotherapies for metastatic renal cell carcinoma still has a role in treating selected patients, a new registry analysis shows.
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home

Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach?
What Do Surrogate End Points Actually Predict?

As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.

UROLOGIC CANCERS NEWS

Patients are 28% more likely to have partial nephrectomy at hospitals offering robotic surgery.

PN, RN Offer Comparable Long-Term Survival for T1b RCC

June 21, 2019

old man in hospital bed

Targeted RCC Therapies Benefit ‘Real World’ Medicare Patients

June 18, 2019

Women who survive breast cancer may have a higher-than-average risk of developing thyroid cancer in

Pazopanib Found Not Beneficial Following Metastasectomy in Metastatic RCC

June 14, 2019

Close to 60% of all patients with VHL will develop RCC or renal cysts.

Combination of ICIs and Cytoreductive Surgery in Metastatic RCC Appears Promising

June 14, 2019

of onabotulinumtoxin A is a safe and effective treatment for oab

Earlier Pembrolizumab Use May Be Beneficial in mUC

June 14, 2019

Next post in General Oncology

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exce

Female Representation on NCCN Guideline Panels Suggests Low Gender Bias